DE2210116A1 - 1,7,7 Tnmethyl 2 norbornan spiro 2 dioxolan (1,3) derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Wirkstoffkomponente in Arzneimitteln - Google Patents
1,7,7 Tnmethyl 2 norbornan spiro 2 dioxolan (1,3) derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Wirkstoffkomponente in ArzneimittelnInfo
- Publication number
- DE2210116A1 DE2210116A1 DE19722210116 DE2210116A DE2210116A1 DE 2210116 A1 DE2210116 A1 DE 2210116A1 DE 19722210116 DE19722210116 DE 19722210116 DE 2210116 A DE2210116 A DE 2210116A DE 2210116 A1 DE2210116 A1 DE 2210116A1
- Authority
- DE
- Germany
- Prior art keywords
- formula
- spiro
- dioxolane
- norbornane
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000004480 active ingredient Substances 0.000 title claims description 5
- 238000000034 method Methods 0.000 title claims description 5
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 3
- 241000723346 Cinnamomum camphora Species 0.000 claims description 3
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 claims description 3
- 229960000846 camphor Drugs 0.000 claims description 3
- 229930008380 camphor Natural products 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims 1
- WMJIFLXGECCUNM-UHFFFAOYSA-N N1(CCCC1)C1N(CCOC1)N1CCCCC1 Chemical compound N1(CCCC1)C1N(CCOC1)N1CCCCC1 WMJIFLXGECCUNM-UHFFFAOYSA-N 0.000 claims 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 229960001789 papaverine Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- -1 Hexamethyleneimino Chemical group 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7109448A FR2129873B1 (enrdf_load_stackoverflow) | 1971-03-18 | 1971-03-18 | |
| FR7300250A FR2215205B2 (enrdf_load_stackoverflow) | 1971-03-18 | 1973-01-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2210116A1 true DE2210116A1 (de) | 1972-09-21 |
Family
ID=26216268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19722210116 Pending DE2210116A1 (de) | 1971-03-18 | 1972-03-02 | 1,7,7 Tnmethyl 2 norbornan spiro 2 dioxolan (1,3) derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Wirkstoffkomponente in Arzneimitteln |
Country Status (8)
| Country | Link |
|---|---|
| BE (1) | BE779924A (enrdf_load_stackoverflow) |
| CA (1) | CA993873A (enrdf_load_stackoverflow) |
| CH (1) | CH535228A (enrdf_load_stackoverflow) |
| DE (1) | DE2210116A1 (enrdf_load_stackoverflow) |
| FR (2) | FR2129873B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1324676A (enrdf_load_stackoverflow) |
| LU (1) | LU64868A1 (enrdf_load_stackoverflow) |
| NL (1) | NL7203535A (enrdf_load_stackoverflow) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS521661B2 (enrdf_load_stackoverflow) * | 1972-05-11 | 1977-01-17 | ||
| US4341665A (en) * | 1980-03-07 | 1982-07-27 | Nippon Petrochemicals Co., Ltd. | Acylnorbornanone acetals, process for preparing the same, and perfume compositions containing the same |
| DE3735555A1 (de) * | 1987-03-07 | 1988-09-15 | Bayer Ag | Aminomethylheterocyclen |
| DE3928707A1 (de) * | 1989-08-30 | 1991-03-07 | Henkel Kgaa | Entzuendungshemmende wirkstoffe fuer kosmetische praeparate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2606909A (en) * | 1947-08-01 | 1952-08-12 | Univ Michigan | Basic dioxolanes |
| AT296299B (de) * | 1968-12-29 | 1972-02-10 | Egyt Gyogyszervegyeszeti Gyar | Verfahren zur Herstellung von neuen cyclischen Ketalderivaten und deren Salzen |
-
1971
- 1971-03-18 FR FR7109448A patent/FR2129873B1/fr not_active Expired
-
1972
- 1972-02-25 GB GB877172A patent/GB1324676A/en not_active Expired
- 1972-02-28 BE BE779924A patent/BE779924A/xx unknown
- 1972-02-29 CH CH287572A patent/CH535228A/fr not_active IP Right Cessation
- 1972-03-01 LU LU64868D patent/LU64868A1/xx unknown
- 1972-03-02 DE DE19722210116 patent/DE2210116A1/de active Pending
- 1972-03-14 CA CA137,110A patent/CA993873A/fr not_active Expired
- 1972-03-16 NL NL7203535A patent/NL7203535A/xx not_active Application Discontinuation
-
1973
- 1973-01-04 FR FR7300250A patent/FR2215205B2/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2129873A1 (enrdf_load_stackoverflow) | 1972-11-03 |
| BE779924A (fr) | 1972-08-28 |
| GB1324676A (en) | 1973-07-25 |
| NL7203535A (enrdf_load_stackoverflow) | 1972-09-20 |
| FR2215205B2 (enrdf_load_stackoverflow) | 1976-09-03 |
| LU64868A1 (enrdf_load_stackoverflow) | 1972-12-07 |
| FR2129873B1 (enrdf_load_stackoverflow) | 1974-09-06 |
| CH535228A (fr) | 1973-03-31 |
| CA993873A (fr) | 1976-07-27 |
| FR2215205A2 (enrdf_load_stackoverflow) | 1974-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2929517A1 (de) | Pinenderivate, verfahren zu ihrer herstellung und sie enthaltende, pharmazeutische zubereitungen | |
| DE2651572A1 (de) | Aminoalkohol-derivat und verfahren zu seiner herstellung | |
| DE1815808B2 (de) | 1 -(Alkanoylamiitophenoxy)-3-alkylamino-2-propanole deren Herstellungsverfahren und pharmazeutische Zusammensetzungen auf deren Basis | |
| DE2210116A1 (de) | 1,7,7 Tnmethyl 2 norbornan spiro 2 dioxolan (1,3) derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Wirkstoffkomponente in Arzneimitteln | |
| DE2802864A1 (de) | 3-isobutoxy-2-pyrrolidino-n-phenyl- n-benzylpropylamin, verfahren zu seiner herstellung und es enthaltende arzneimittel | |
| DE2745598A1 (de) | Arylschwefelverbindungen, verfahren zu ihrer herstellung und sie enthaltendes pharmazeutisches mittel | |
| DE10004572A1 (de) | Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel | |
| DE1695111B1 (de) | Indolderivate | |
| DE2515770C2 (de) | Prostaglandinanaloge, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| DE2117358C3 (de) | 4'-Aminomethyl-spiro eckige Klammer auf dibenzo eckige Klammer auf a,d eckige Klammer zu cycloheptadi-(oder tri-) en-5,2'-(1 \3'-dioxolan) eckige Klammer zu -Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltene Arzneimittel | |
| DE1470139C3 (de) | 5,11-Dihydrodibenz eckige Klammer auf b,e eckige Klammer zu-1,4-oxazepine und Verfahren zu ihrer Herstellung | |
| DE2941597A1 (de) | Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen | |
| DE2823834C2 (de) | Farnesylcarbonsäure-&alpha;-bisabololester, Verfahren zu dessen Herstellung und diesen enthaltendes Mittel | |
| DE2333831A1 (de) | 1-(2'-benzoyl-aeth-1'-yl)-2-(4"cinnamyl-piperazin-1"-yl-methyl)benzimidazole, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
| DE2440919A1 (de) | Prostaglandinanaloge, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
| DE1966587A1 (de) | Neue thioamide und verfahren zu ihrer herstellung | |
| DE2304224C3 (de) | 4'-Aminomethyl-dibenzo(b,e)-l 1oxepin-2'-spiro-l', 3'-dioxolan-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2013668A1 (de) | Neue Oxazolidin-2-one, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2166869C3 (de) | 4-a-Naphthoxy-3-hydroxy-butyramidoxim, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Mittel | |
| DE2200766C3 (de) | 2-Methyl-4-N-heteromethyl-2-(3,4,5trimethoxyphenyl)-dioxolane | |
| DE2235941C3 (de) | 4,7-Dimethoxybenzofuranderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| EP0133318B1 (de) | Cycloaliphatische Aminosulfonsäurederivate, Verfahren zu deren Herstellung und Arzneimittel zur Bekämpfung von Herz- und Gefässkrankheiten | |
| DE2816627A1 (de) | 2-(n-amino-isoindolinyl)-imidazolin und verfahren zu seiner herstellung | |
| DE2519163C2 (de) | 2-Formyl-1,2,3,4-tetrahydro-5-(2-hydroxy-3-tert.butyl-aminopropoxy)-isochinolin, dessen Salze, Verfahren zu deren Herstellung und ihre Verwendung | |
| AT371810B (de) | Verfahren zum herstellen von neuen chinazolinen und ihren salzen |